



Cornelia L. Dekker, M.D.

Professor (Research) of Pediatrics (Infectious Diseases), Emerita
Pediatrics - Infectious Diseases

CONTACT INFORMATION

- **Alternate Contact**

Nancy Greguras Wilkening - Administrative Associate

Email greguras@stanford.edu

Tel (650) 498-6227

Bio

BIO

Dr. Cornelia Dekker is a Pediatric Infectious Diseases physician who came to Stanford after a 12-year career in vaccine clinical development at Lederle Biologicals and Chiron Vaccines where she served as Vice President, Clinical Research and Medical Affairs. In this position, she was responsible for the clinical development of 18 vaccine candidates, including those for HSV, HIV, meningococcus A and C, adjuvanted influenza, acellular pertussis-DT, hepatitis A, hepatitis B, hepatitis C, H. influenza type b and CMV. During her tenure, Chiron's clinical program included testing of a recombinantly produced HSV gD2/gB2 vaccine with MF59 adjuvant for the amelioration of established genital herpes infection and the prevention of genital herpes in high-risk adults, and the first influenza vaccine combined with the MF59 adjuvant that was licensed initially in Europe and South America and just recently also in the US.

Dr. Dekker joined the Stanford University School of Medicine faculty in the Division of Pediatric Infectious Diseases and was named Medical Director of the Stanford-LPCH Vaccine Program in 1999. She has served as the Stanford PI on NIH-sponsored Vaccine and Treatment Evaluation Unit subcontracts to study new vaccine candidates and on a CDC-sponsored Clinical Immunization Safety Assessment Center contract evaluating safety of licensed vaccines. She leads the Stanford Clinical Core for NIH-sponsored studies looking at the detailed immune responses to influenza vaccines in children compared with young and elderly adults that has expanded to investigate genetic factors by also studying responses of identical and fraternal twins. Dr. Dekker's expertise in vaccines has been tapped by NIH to serve on several vaccine safety and data monitoring boards, and she currently is Chair of the HIV Vaccine Trial Network Safety Monitoring Board. On the National Vaccine Advisory Committee, she served on the Vaccine Safety Working Group and H1N1 Vaccine Safety Subgroup among others. In 2016, she was named Medical Director for the Stanford Clinical and Translational Research Unit.

ACADEMIC APPOINTMENTS

- Professor Emeritus-Hourly, Pediatrics - Infectious Diseases
- Member, Maternal & Child Health Research Institute (MCHRI)

ADMINISTRATIVE APPOINTMENTS

- Medical Director, Stanford-LPCH Vaccine Program, (1999-2019)
- Medical Director, Stanford Clinical and Translational Research Unit, (2016-2019)
- IRB Reviewer, Stanford Administrative Panel on Human Subjects in Medical Research, Panel 3, (2002- present)

- Member, Stanford Institute for Immunity, Transplantation and Infection, (2005- present)
- Member, Department of Pediatrics Research Advisory Committee, (2009-2015)
- Member, Department of Pediatrics Administrative Advisory Committee, (2008-2009)
- Member, Stanford GCRC Advisory Committee, (2006-2008)

HONORS AND AWARDS

- Fellow, Pediatric Infectious Diseases Society (2017-present)
- Fellow, Infectious Diseases Society of America (1998-present)
- Member, Pediatric Infectious Diseases Society (1998-present)
- Junior Faculty Award, SmithKlein Beecham (07/05/00-07/04/02)
- Excellence in Teaching, Stanford Univ. School of Medicine (06/23/08)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Chair, NIH DMID SMC: Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area (2017 - present)
- Chair, NIH DMID SMC: Phase I Placebo-Controlled Inactivated Whole Virus ZIKA Virus Vaccine in Flavivirus Naive Subjects (2016 - present)
- Chair, NIH DMID SMC: A Phase I, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) with Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects (2016 - present)
- Chair, NIH DMID SMC: Phase I Study to Determine the Human Infectious Dose Causing 50% Infection with the GII.2 Snow Mountain Norovirus Filtrate, SNM (2013 - present)
- Chair, NIH DMID SMC: Phase I Study of the GII.4 Norovirus Filtrate, CIN 1 (2013 - 2015)
- Member, NIH DMID SMC: 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 through 74 Years of Age (2012 - present)
- Member, External Data Monitoring Committee for ACC-001 (vanutide cridifcar) Alzheimer's disease vaccine (2011 - 2014)
- Member and Chair, HIV Vaccine Trial Network Safety Monitoring Board (Chair 2014-2019) (2009 - 2019)
- Member, NVAC H1N1 Subgroup (2009 - 2010)
- Member, NIH DMID SMC Evaluation of a Challenge Pool of Norwalk Virus Inocula in Human Subjects (2008 - present)
- Member, NVAC Vaccine Safety Working Group (2008 - 2011)
- Member, NIH DMID Phase 1A Clinical Study with DAS181 Safety Monitoring Committee (2007 - 2010)
- Member, National Vaccine Advisory Committee (NVAC) (2005 - 2010)
- Co-chair, NVAC Subcommittee on Vaccine Development and Supply (2005 - 2008)
- Chair (Pediatric), NIH DMID/Sanofi Pasteur Inactivated Influenza A/H5N1 Vaccine Data Safety Monitoring Board (2005 - 2007)
- Co-chair, NVAC Working Group on Regulatory Harmonization (2005 - 2006)
- Member, Trustee Committee, California Association of Independent Schools (2004 - 2007)
- President, Bentley School Board of Trustees (2001 - 2004)
- Trustee, Bentley School Board of Trustees (1997 - 2004)

PROFESSIONAL EDUCATION

- B.S., Michigan State University , Microbiology & Public Health, Human Clinical Medicine (1973)
- M.D., Michigan State University , Medicine (1976)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The overarching theme of our research activities is human response to natural virus infection and to vaccines. We have conducted several studies of adult, toddler and infant immune response to initial infection with human cytomegalovirus (HCMV). Our largest was a project in which we screened 20,000 newborn infants at Stanford, El Camino and Santa Clara Valley Hospitals for evidence of congenital HCMV infection. Those infants identified as being infected were enrolled into a 3-year prospective study for medical, audiology and immunology screening. The hearing screening portion was designed to identify, as early as possible, infants who develop sensorineural hearing loss as a result of this infection.

A second area of clinical research is supported by Dr. Mark Davis' NIH-funded CCHI U19 project entitled "Protective Mechanisms Against Pandemic Respiratory Virus" and the HIPC U19 project entitled "Vaccination and Infection: Indicators of Immunological Health and Responsiveness". To provide samples for the lab projects we immunize children and adults (including elderly) with one of four different, licensed influenza vaccines (Fluzone, Fluzone high-dose, Fluzone Intradermal or FluMist) to study in detail the immune response to immunization given by various routes. Blood samples collected from study subjects are analyzed for influenza-specific B and T-cell responses as well as gene expression studies and cytokine analyses. Our latest studies have focused on genetic vs. environmental influences by enrolling fraternal and identical twins. Under the HIPC U19, we conducted a study of the shingles vaccine in twins and non-twin adults for a close examination of T-cell responses. We also have conducted a study of natural influenza infection for the past 4 years in children and adults to collect NP swabs and blood samples in collaboration with researchers in the Greenberg lab who study how B cells and T cells respond to influenza virus infection at these two sites.

Our group also was funded as part of the Vaccine Treatment and Evaluation Units by NIH through our collaborators at Vanderbilt University. We conducted studies of avian, novel H1N1 and seasonal influenza vaccines and a new malaria vaccine under this subcontract. A study of a new DNA vaccine against influenza was conducted under sponsorship by EMMES Corporation and the Vaccine Research Center at NIH.

A fourth area of interest has been vaccine safety. Stanford was one of six designated Centers for Immunization Safety Assessment (CISA) sponsored by the CDC for a 10 year period. The network provided consultation to CDC on evaluation and treatment of adverse events following immunization with licensed vaccines, developed protocols to study certain events that occur following immunization (including hypersensitivity reactions, safety of live viral vaccines in immunodeficient children, genetics study of Guillain-Barre syndrome patients). We also have collaborated with Dr. Greg Enns on an NIH-sponsored study of the safety of influenza vaccine and its metabolic effects in patients with the MELAS mtDNA polymorphisms.

For further information about ongoing studies, please refer to our website at <http://vaccines.stanford.edu>.

CLINICAL TRIALS

- Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031), Not Recruiting
- Adenovirus Vaccine for Malaria, Not Recruiting
- B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011), Not Recruiting
- B-cell Immunity to Influenza (SLVP017)- Year 1, 2009, Not Recruiting
- B-cell Immunity to Influenza (SLVP017)- Year 5, 2013, Not Recruiting
- Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017), Not Recruiting
- Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort, Not Recruiting
- Genetic and Environmental Factors in the Response to Influenza Vaccination, Not Recruiting
- Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029), Not Recruiting

- Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age, Not Recruiting
- Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization, Not Recruiting
- Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014), Not Recruiting
- Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024), Not Recruiting
- Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS), Not Recruiting
- Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations, Not Recruiting
- T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020, Not Recruiting
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009, Not Recruiting
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010, Not Recruiting
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011, Not Recruiting
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012, Not Recruiting
- T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013, Not Recruiting
- The Human Mucosal Immune Responses to Influenza Virus (SLVP026), Not Recruiting
- The Influence of Chronic CMV Infection on Influenza Vaccine Responses, Not Recruiting
- Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032), Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Infectious Diseases (Fellowship Program)

Publications

PUBLICATIONS

- **Acute Respiratory Illness Is Associated with Memory T Cell Differentiation and Other Immune Cell Changes in an Age-Associated Manner.** *ImmunoHorizons*
Ugale, S. S., Holmes, T. H., Maysel-Auslender, S., Boyd, S. D., Dekker, C. L., Davis, M. M., Maecker, H. T.
2023; 7 (9): 611-618
- **Considerations for unblinding individual study participants during vaccine trials.** *Vaccine*
Halsey, N., Evans, S., Santosham, M., Hacker, A., Edwards, K. M., Chandler, R. E., Dudley, M. Z., Dekker, C. L., Al-Abri, S., Arora, N., Buttery, J., Dodoo, A., Eskola, et al
2023
- **KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.** *Science (New York, N.Y.)*
Li, J., Zaslavsky, M., Su, Y., Guo, J., Sikora, M. J., van Unen, V., Christophersen, A., Chiou, S., Chen, L., Li, J., Ji, X., Wilhelmy, J., McSween, et al
2022: eabi9591
- **Author Correction: An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging.** *Nature aging*
Sayed, N., Huang, Y., Nguyen, K., Krejciova-Rajaniemi, Z., Grawe, A. P., Gao, T., Tibshirani, R., Hastie, T., Alpert, A., Cui, L., Kuznetsova, T., Rosenberg-Hasson, Y., Ostan, et al
2021; 1 (8): 748
- **An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging.** *Nature aging*
Sayed, N., Huang, Y., Nguyen, K., Krejciova-Rajaniemi, Z., Grawe, A. P., Gao, T., Tibshirani, R., Hastie, T., Alpert, A., Cui, L., Kuznetsova, T., Rosenberg-Hasson, Y., Ostan, et al
2021; 1: 598-615
- **The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety** *VACCINE*

- Black, S. B., Law, B., Chen, R. T., Dekker, C. L., Sturkenboom, M., Huang, W., Gurwith, M., Poland, G.
2021; 39 (19): 2712-2718
- **Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.** *Vaccine*
Munoz, F. M., Cramer, J. P., Dekker, C. L., Dudley, M. Z., Graham, B. S., Gurwith, M., Law, B., Perlman, S., Polack, F. P., Spergel, J. M., Van Braeckel, E., Ward, B. J., Didierlaurent, et al
2021
 - **Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination.** *Proceedings of the National Academy of Sciences of the United States of America*
Lopez Angel, C. J., Pham, E. A., Du, H. n., Vallania, F. n., Fram, B. J., Perez, K. n., Nguyen, T. n., Rosenberg-Hasson, Y. n., Ahmed, A. n., Dekker, C. L., Grant, P. M., Khatri, P. n., Maecker, et al
2021; 118 (14)
 - **Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.**
Lambert, P., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., Molrine, D. C., Perlman, S., Picard-Fraser, et al
2020
 - **Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics.** *Cell reports*
Horns, F., Dekker, C. L., Quake, S. R.
2020; 30 (3): 905
 - **The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system.** *Scientific data*
Tomic, A., Tomic, I., Dekker, C. L., Maecker, H. T., Davis, M. M.
2019; 6 (1): 214
 - **Diminished B-Cell Response After Repeat Influenza Vaccination** *JOURNAL OF INFECTIOUS DISEASES*
Sanyal, M., Holmes, T. H., Maecker, H. T., Albrecht, R. A., Dekker, C. L., He, X., Greenberg, H. B.
2019; 219 (10): 1586-95
 - **Distinct phenotype of CD4(+) T cells driving celiac disease identified in multiple autoimmune conditions** *NATURE MEDICINE*
Christophersen, A., Lund, E. G., Snir, O., Sola, E., Kanduri, C., Dahal-Koirala, S., Zuhlke, S., Molberg, O., Utz, P. J., Rohani-Pichavant, M., Simard, J. F., Dekker, C. L., Lundin, et al
2019; 25 (5): 734-+
 - **The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease** *CONTEMPORARY CLINICAL TRIALS*
Roberts, S. C., Jain, S., Tremoulet, A. H., Kim, K. K., Burns, J. C., Anand, V., Anderson, M., Ang, J., Ansusinha, E., Ardit, M., Ashouri, N., Bartlett, A., Chatterjee, et al
2019; 79: 98-103
 - **A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring** *NATURE MEDICINE*
Alpert, A., Pickman, Y., Leipold, M., Rosenberg-Hasson, Y., Ji, X., Gaujoux, R., Rabani, H., Starosvetsky, E., Kveler, K., Schaffert, S., Furman, D., Caspi, O., Rosenschein, et al
2019; 25 (3): 487-+
 - **Signatures of selection in the human antibody repertoire: Selective sweeps, competing subclones, and neutral drift** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Horns, F., Vollmers, C., Dekker, C. L., Quake, S. R.
2019; 116 (4): 1261-66
 - **SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses.** *Journal of immunology (Baltimore, Md. : 1950)*
Tomic, A. n., Tomic, I. n., Rosenberg-Hasson, Y. n., Dekker, C. L., Maecker, H. T., Davis, M. M.
2019
 - **Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase I clinical trial.** *PLoS one*
Carter, C., Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, et al

2019; 14 (9): e0222178

- **Determinants governing T cell receptor α/β -chain pairing in repertoire formation of identical twins.** *Proceedings of the National Academy of Sciences of the United States of America*
Tanno, H. n., Gould, T. M., McDaniel, J. R., Cao, W. n., Tanno, Y. n., Durrett, R. E., Park, D. n., Cate, S. J., Hildebrand, W. H., Dekker, C. L., Tian, L. n., Weyand, C. M., Georgiou, et al
2019
- **Pregnancy-Induced Alterations in NK Cell Phenotype and Function.** *Frontiers in immunology*
Le Gars, M., Seiler, C., Kay, A. W., Bayless, N. L., Starosvetsky, E., Moore, L., Shen-Orr, S. S., Aziz, N., Khatri, P., Dekker, C. L., Swan, G. E., Davis, M. M., Holmes, et al
2019; 10: 2469
- **Diminished B-cell response after repeat influenza vaccination.** *The Journal of infectious diseases*
Sanyal, M., Holmes, T. H., Maecker, H., Albrecht, R. A., Dekker, C. L., He, X., Greenberg, H. B.
2018
- **Plasmablast antibody repertoires in elderly influenza vaccine responders exhibit restricted diversity but increased breadth of binding across influenza strains** *CLINICAL IMMUNOLOGY*
Ju, C., Blum, L. K., Kongpachith, S., Lingampalli, N., Mao, R., Brodin, P., Dekker, C. L., Davis, M. M., Robinson, W. H.
2018; 193: 70–79
- **Single-Cell Chromatin Modification Profiling Reveals Increased Epigenetic Variations with Aging** *CELL*
Cheung, P., Vallania, F., Warsinske, H. C., Donato, M., Schaffert, S., Chang, S. E., Dvorak, M., Dekker, C. L., Davis, M. M., Utz, P. J., Khatri, P., Kuo, A. J.
2018; 173 (6): 1385–+
- **Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods for Molecular Influenza Testing in Emergency Department Patients** *ANNALS OF EMERGENCY MEDICINE*
Frazee, B. W., de la Guardia, A., Alter, H., Chen, C. G., Fuentes, E. L., Holzer, A. K., Lolos, M., Mitra, D., Vohra, J., Dekker, C. L.
2018; 71 (4): 509–17
- **Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis** *SCIENCE IMMUNOLOGY*
de Bourcy, C. A., Dekker, C. L., Davis, M. M., Nicolls, M. R., Quake, S. R.
2017; 2 (15)
- **Continuous immunotypes describe human immune variation and predict diverse responses** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Kaczorowski, K. J., Shekhar, K., Nkulikiyimfura, D., Dekker, C. L., Maecker, H., Davis, M. M., Chakraborty, A. K., Brodin, P.
2017; 114 (30): E6097–E6106
- **Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states** *NATURE MEDICINE*
Furman, D., Chang, J., Lartigue, L., Bolen, C. R., Haddad, F., Gaudilliere, B., Ganio, E. A., Fragiadakis, G. K., Spitzer, M. H., Douchet, I., Daburon, S., Moreau, J., Nolan, et al
2017; 23 (2): 174-184
- **Phylogenetic analysis of the human antibody repertoire reveals quantitative signatures of immune senescence and aging** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
de Bourcy, C. F., Angel, C. J., Vollmers, C., Dekker, C. L., Davis, M. M., Quake, S. R.
2017; 114 (5): 1105-1110
- **Increased Proinflammatory Responses of Monocytes and Plasmacytoid Dendritic Cells to Influenza A Virus Infection During Pregnancy** *JOURNAL OF INFECTIOUS DISEASES*
Le Gars, M., Kay, A. W., Bayless, N. L., Aziz, N., Dekker, C. L., Swan, G. E., Davis, M. M., Blish, C. A.
2016; 214 (11): 1666-1671
- **Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination.** *Nature medicine*
Lee, J., Boutz, D. R., Chromikova, V., Joyce, M. G., Vollmers, C., Leung, K., Horton, A. P., DeKosky, B. J., Lee, C., Lavinder, J. J., Murrin, E. M., Chrysostomou, C., Hoi, et al
2016
- **Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans.** *Cell systems*

- Shen-Orr, S. S., Furman, D., Kidd, B. A., Hadad, F., Lovelace, P., Huang, Y., Rosenberg-Hasson, Y., Mackey, S., Grisar, F. A., Pickman, Y., Maecker, H. T., Chien, Y., Dekker, et al
2016; 3 (4): 374-384 e4
- **Defective T Memory Cell Differentiation after Varicella Zoster Vaccination in Older Individuals.** *PLoS pathogens*
Qi, Q., Cavanagh, M. M., Le Saux, S., Wagar, L. E., Mackey, S., Hu, J., Maecker, H., Swan, G. E., Davis, M. M., Dekker, C. L., Tian, L., Weyand, C. M., Goronzy, et al
2016; 12 (10)
 - **Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching** *ELIFE*
Horns, F., Vollmers, C., Croote, D., Mackey, S. F., Swan, G. E., Dekker, C. L., Davis, M. M., Quake, S. R.
2016; 5
 - **Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.** *Science translational medicine*
Qi, Q., Cavanagh, M. M., Le Saux, S., Namkoong, H., Kim, C., Turgano, E., Liu, Y., Wang, C., Mackey, S., Swan, G. E., Dekker, C. L., Olshen, R. A., Boyd, et al
2016; 8 (332): 332ra46-?
 - **Individual heritable differences result in unique cell lymphocyte receptor repertoires of naive and antigen-experienced cells** *NATURE COMMUNICATIONS*
Rubelt, F., Bolen, C. R., McGuire, H. M., Vander Heiden, J. A., Gadala-Maria, D., Levin, M., Euskirchen, G. M., Mamedov, M. R., Swan, G. E., Dekker, C. L., Cowell, L. G., Kleinstein, S. H., Davis, et al
2016; 7
 - **Longitudinal Kinetics of Cytomegalovirus-Specific T-Cell Immunity and Viral Replication in Infants With Congenital Cytomegalovirus Infection.** *Journal of the Pediatric Infectious Diseases Society*
Chen, S. F., Holmes, T. H., Slifer, T., Ramachandran, V., Mackey, S., Hebson, C., Arvin, A. M., Lewis, D. B., Dekker, C. L.
2016; 5 (1): 14-20
 - **Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals** *CELL REPORTS*
Fang, F., Yu, M., Cavanagh, M. M., Saunders, J. H., Qi, Q., Ye, Z., Le Saux, S., Sultan, W., Turgano, E., Dekker, C. L., Tian, L., Weyand, C. M., Goronzy, et al
2016; 14 (5): 1218-1231
 - **Human B-cell isotype switching origins of IgE** *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Looney, T. J., Lee, J., Roskin, K. M., Hoh, R. A., King, J., Glanville, J., Liu, Y., Pham, T. D., Dekker, C. L., Davis, M. M., Boyd, S. D.
2016; 137 (2): 579-?
 - **Mapping epitopes of U1-70K autoantibodies at single-amino acid resolution** *AUTOIMMUNITY*
Haddon, D. J., Jarrell, J. A., Diep, V. K., Wand, H. E., Price, J. V., Tangsombatvisit, S., Credo, G. M., Mackey, S., Dekker, C. L., Baechler, E. C., Liu, C. L., Varma, M., Utz, et al
2015; 48 (8): 513-523
 - **Pregnancy Does Not Attenuate the Antibody or Plasmablast Response to Inactivated Influenza Vaccine.** *journal of infectious diseases*
Kay, A. W., Bayless, N. L., Fukuyama, J., Aziz, N., Dekker, C. L., Mackey, S., Swan, G. E., Davis, M. M., Blish, C. A.
2015; 212 (6): 861-870
 - **IgH sequences in common variable immune deficiency reveal altered B cell development and selection.** *Science translational medicine*
Roskin, K. M., Simchoni, N., Liu, Y., Lee, J., Seo, K., Hoh, R. A., Pham, T., Park, J. H., Furman, D., Dekker, C. L., Davis, M. M., James, J. A., Nadeau, et al
2015; 7 (302): 302ra135-?
 - **Human B-cell isotype switching origins of IgE.** *The Journal of allergy and clinical immunology*
Looney, T. J., Lee, J. Y., Roskin, K. M., Hoh, R. A., King, J., Glanville, J., Liu, Y., Pham, T. D., Dekker, C. L., Davis, M. M., Boyd, S. D.
2015
 - **Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.** *journal of infectious diseases*
He, X., Holmes, T. H., Sanyal, M., Albrecht, R. A., Garcia-Sastre, A., Dekker, C. L., Davis, M. M., Greenberg, H. B.
2015; 211 (7): 1051-1059
 - **Cytomegalovirus infection enhances the immune response to influenza** *SCIENCE TRANSLATIONAL MEDICINE*
Furman, D., Jovic, V., Sharma, S., Shen-Orr, S. S., Angel, C. J., Onengut-Gumuscu, S., Kidd, B. A., Maecker, H. T., Concannon, P., Dekker, C. L., Thomas, P. G., Davis, M. M.
2015; 7 (281)

- **Variation in the human immune system is largely driven by non-heritable influences.** *Cell*
Brodin, P., Jovic, V., Gao, T., Bhattacharya, S., Angel, C. J., Furman, D., Shen-Orr, S., Dekker, C. L., Swan, G. E., Butte, A. J., Maecker, H. T., Davis, M. M.
2015; 160 (1-2): 37-47
- **B-cell repertoire responses to varicella-zoster vaccination in human identical twins.** *Proceedings of the National Academy of Sciences of the United States of America*
Wang, C., Liu, Y., Cavanagh, M. M., Le Saux, S., Qi, Q., Roskin, K. M., Looney, T. J., Lee, J., Dixit, V., Dekker, C. L., Swan, G. E., Goronzy, J. J., Boyd, et al
2015; 112 (2): 500-505
- **Perinatal outcomes in infants with congenitally and postnatally acquired cytomegalovirus infection**
Aziz, N., McDowell, M., Guo, F., Lee, H., Srinivas, N., Gutierrez, K., Benitz, W., Dekker, C., Folkins, A., Pinsky, B., Norton, M.
MOSBY-ELSEVIER.2015: S336
- **The Split Virus Influenza Vaccine rapidly activates immune cells through Fc gamma receptors** *VACCINE*
O'Gorman, W. E., Huang, H., Wei, Y., Davis, K. L., Leipold, M. D., Bendall, S. C., Kidd, B. A., Dekker, C. L., Maecker, H. T., Chien, Y., Davis, M. M.
2014; 32 (45): 5989-5997
- **Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Kay, A. W., Fukuyama, J., Aziz, N., Dekker, C. L., Mackey, S., Swan, G. E., Davis, M. M., Holmes, S., Blish, C. A.
2014; 111 (40): 14506-14511
- **Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines.** *journal of infectious diseases*
Sasaki, S., Holmes, T. H., Albrecht, R. A., García-Sastre, A., Dekker, C. L., He, X., Greenberg, H. B.
2014; 210 (6): 865-874
- **Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements.** *Cell host & microbe*
Jackson, K. J., Liu, Y., Roskin, K. M., Glanville, J., Hoh, R. A., Seo, K., Marshall, E. L., Gurley, T. C., Moody, M. A., Haynes, B. F., Walter, E. B., Liao, H., Albrecht, et al
2014; 16 (1): 105-114
- **The split-virus influenza vaccine activates Fc gamma receptors instead of Toll-like receptors**
O'Gorman, W., Huang, H., Wei, Y., Davis, K., Leipold, M., Bendall, S., Kidd, B., Dekker, C., Maecker, H., Chien, Y., Davis, M.
AMER ASSOC IMMUNOLOGISTS.2014
- **Live Vaccine Use and Safety in DiGeorge Syndrome.** *Pediatrics*
Hofstetter, A. M., Jakob, K., Klein, N. P., Dekker, C. L., Edwards, K. M., Halsey, N. A., Baxter, R., Williams, S. E., Graham, P. L., LaRussa, P.
2014; 133 (4): e946-54
- **Effects of Aging, Cytomegalovirus Infection, and EBV Infection on Human B Cell Repertoires** *JOURNAL OF IMMUNOLOGY*
Wang, C., Liu, Y., Xu, L. T., Jackson, K. J., Roskin, K. M., Pham, T. D., Laserson, J., Marshall, E. L., Seo, K., Lee, J., Furman, D., Koller, D., Dekker, et al
2014; 192 (2): 603-611
- **Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination.** *Proceedings of the National Academy of Sciences of the United States of America*
Furman, D., Hejblum, B. P., Simon, N., Jovic, V., Dekker, C. L., Thiébaud, R., Tibshirani, R. J., Davis, M. M.
2014; 111 (2): 869-874
- **Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.** *Molecular systems biology*
Furman, D., Jovic, V., Kidd, B., Shen-Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H. T., Utz, P. J., Dekker, C. L., Koller, et al
2014; 10: 750-?
- **Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS** *VACCINE*
Halsey, N. A., Griffioen, M., Dreskin, S. C., Dekker, C. L., Wood, R., Sharma, D., Jones, J. F., LaRussa, P. S., Garner, J., Berger, M., Proveaux, T., Vellozzi, C., Broder, et al
2013; 31 (51): 6107-6112
- **Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults.** *Human vaccines & immunotherapeutics*
Creech, C. B., Dekker, C. L., Ho, D., Phillips, S., Mackey, S., Murray-Krezan, C., Grazia Pau, M., Hendriks, J., Brown, V., Dally, L. G., Versteeg, I., Edwards, K. M.

2013; 9 (12): 2548-2557

- **Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry.** *Science translational medicine*
Horowitz, A., Strauss-Albee, D. M., Leipold, M., Kubo, J., Nemat-Gorgani, N., Dogan, O. C., Dekker, C. L., Mackey, S., Maecker, H., Swan, G. E., Davis, M. M., Norman, P. J., Guethlein, et al
2013; 5 (208): 208ra145-?
- **Genetic measurement of memory B-cell recall using antibody repertoire sequencing** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Vollmers, C., Sit, R. V., Weinstein, J. A., Dekker, C. L., Quake, S. R.
2013; 110 (33): 13463-13468
- **Comprehensive assessment of serious adverse events following immunization by health care providers.** *journal of pediatrics*
Williams, S. E., Edwards, K. M., Baxter, R. P., LaRussa, P. S., Halsey, N. A., Dekker, C. L., Vellozzi, C., Marchant, C. D., Donofrio, P. D., Reimschisel, T. E., Berger, M., Gidudu, J. F., Klein, et al
2013; 162 (6): 1276-?
- **Quantifying the unanticipated diversity of the human NK cell repertoire**
Strauss-Albee, D., Horowitz, A., Dogan, O., Mackey, S., Swan, G., Dekker, C., Davis, M., Parham, P., Blish, C.
AMER ASSOC IMMUNOLOGISTS.2013
- **Influenza antigen microarrays reveal reactivity signatures associated with effective response to seasonal trivalent influenza vaccination**
Price, J., Jarrell, J., Furman, D., Kattah, N., Newell, E., Dekker, C., Davis, M., Utz, P.
AMER ASSOC IMMUNOLOGISTS.2013
- **Discovering the determinants of diversity in the human NK cell repertoire by mass cytometry**
Horowitz, A., Strauss-Albee, D., Nemat-Gorgani, N., Dogan, O., Dekker, C., Mackey, S., Swan, G., Davis, M., Norman, P., Guethlein, L., Parham, P., Blish, C.
AMER ASSOC IMMUNOLOGISTS.2013
- **Lineage structure of the human antibody repertoire in response to influenza vaccination.** *Science translational medicine*
Jiang, N., He, J., Weinstein, J. A., Penland, L., Sasaki, S., He, X., Dekker, C. L., Zheng, N., Huang, M., Sullivan, M., Wilson, P. C., Greenberg, H. B., Davis, et al
2013; 5 (171): 171ra19-?
- **Clinical Assessment of Serious Adverse Events in Children Receiving 2009 H1N1 Vaccination** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Pahud, B. A., Williams, S. E., Dekker, C. L., Halsey, N., LaRussa, P., Baxter, R. P., Klein, N. P., Marchant, C. D., Sparks, R. C., Jakob, K., Aukes, L., Swope, S., Barnett, et al
2013; 32 (2): 163-168
- **Heterovariant Cross-Reactive B-Cell Responses Induced by the 2009 Pandemic Influenza Virus A Subtype H1N1 Vaccine** *JOURNAL OF INFECTIOUS DISEASES*
He, X., Sasaki, S., Baer, J., Khurana, S., Golding, H., Treanor, J. J., Topham, D. J., Sangster, M. Y., Jin, H., Dekker, C. L., Subbarao, K., Greenberg, H. B.
2013; 207 (2): 288-296
- **Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.** *PloS one*
Price, J. V., Jarrell, J. A., Furman, D., Kattah, N. H., Newell, E., Dekker, C. L., Davis, M. M., Utz, P. J.
2013; 8 (5)
- **Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.** *Molecular systems biology*
Furman, D., Jovic, V., Kidd, B., Shen-Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H. T., Utz, P. J., Dekker, C. L., Koller, et al
2013; 9: 659-?
- **Biologically plausible and evidence-based risk intervals in immunization safety research** *VACCINE*
Rowhani-Rahbar, A., Klein, N. P., Dekker, C. L., Edwards, K. M., Marchant, C. D., Vellozzi, C., Fireman, B., Sejvar, J. J., Halsey, N. A., Baxter, R.
2012; 31 (1): 271-277
- **Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)** *VACCINE*
Loughlin, A. M., Marchant, C. D., Adams, W., Barnett, E., Baxter, R., Black, S., Casey, C., Dekker, C., Edwards, K. M., Klein, J., Klein, N. P., LaRussah, P., Sparks, et al
2012; 30 (50): 7253-7259
- **Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons** *JOURNAL OF INFECTIOUS DISEASES*

- Jackson, L. A., Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Roupael, N., Noah, et al
2012; 206 (6): 811-820
- **Algorithm to assess causality after individual adverse events following immunizations** *VACCINE*
Halsey, N. A., Edwards, K. M., Dekker, C. L., Klein, N. P., Baxter, R., LaRussa, P., Marchant, C., Slade, B., Vellozzi, C.
2012; 30 (39): 5791-5798
 - **Lack of association between childhood immunizations and encephalitis in California, 1998-2008** *VACCINE*
Pahud, B. A., Rowhani-Rahbar, A., Glaser, C., Gavali, S., Salibay, C. J., Fireman, B., Dekker, C. L.
2012; 30 (2): 247-253
 - **Developing the next generation of vaccinologists** *VACCINE*
Klein, N. P., Gidudu, J., Qiang, Y., Pahud, B., Rowhani-Rahbar, A., Baxter, R., Dekker, C. L., Edwards, K. M., Halsey, N. A., LaRussa, P., Marchant, C., Tokars, J. I., DeStefano, et al
2011; 29 (50): 9296-9297
 - **Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive Adults** *JOURNAL OF INFECTIOUS DISEASES*
Kennedy, J. S., Gurwith, M., Dekker, C. L., Frey, S. E., Edwards, K. M., Kenner, J., Lock, M., Empig, C., Morikawa, S., Saijo, M., Yokote, H., Karem, K., Damon, et al
2011; 204 (9): 1395-1402
 - **Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination** *VACCINE*
Williams, S. E., Pahud, B. A., Vellozzi, C., Donofrio, P. D., Dekker, C. L., Halsey, N., Klein, N. P., Baxter, R. P., Marchant, C. D., LaRussa, P. S., Barnett, E. D., Tokars, J. I., McGeeney, et al
2011; 29 (46): 8302-8308
 - **Rotavirus shedding in premature infants following first immunization** *VACCINE*
Smith, C. K., McNeal, M. M., Meyer, N. R., Haase, S., Dekker, C. L.
2011; 29 (45): 8141-8146
 - **Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009** *VACCINE*
Williams, S. E., Klein, N. P., Halsey, N., Dekker, C. L., Baxter, R. P., Marchant, C. D., LaRussa, P. S., Sparks, R. C., Tokars, J. I., Pahud, B. A., Aukes, L., Jakob, K., Coronel, et al
2011; 29 (40): 6920-6927
 - **Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone (R)) administered by intradermal and intramuscular route in healthy adults** *VACCINE*
Frenck, R. W., Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, et al
2011; 29 (34): 5666-5674
 - **Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies** *JOURNAL OF CLINICAL INVESTIGATION*
Sasaki, S., Sullivan, M., Narvaez, C. F., Holmes, T. H., Furman, D., Zheng, N., Nishtala, M., Wrammert, J., Smith, K., James, J. A., Dekker, C. L., Davis, M. M., Wilson, et al
2011; 121 (8): 3109-3119
 - **Biologically Plausible Risk Intervals To Assess Febrile Seizure Following Immunization with Influenza and Pneumococcal Conjugate Vaccines**
Rowhani-Rahbar, A., Klein, N. P., Dekker, C. L., Edwards, K. M., Vellozzi, C., Halsey, N. A., Baxter, R. P., CISA
WILEY-BLACKWELL.2011: S243
 - **Attitudes and Beliefs of Parents Concerned About Vaccines: Impact of Timing of Immunization Information** *PEDIATRICS*
Vannice, K. S., Salmon, D. A., Shui, I., Omer, S. B., Kissner, J., Edwards, K. M., Sparks, R., Dekker, C. L., Klein, N. P., Gust, D. A.
2011; 127: S120-S126
 - **Understanding the Role of Human Variation in Vaccine Adverse Events: The Clinical Immunization Safety Assessment Network** *PEDIATRICS*
Larussa, P. S., Edwards, K. M., Dekker, C. L., Klein, N. P., Halsey, N. A., Marchant, C., Baxter, R., Engler, R. J., Kissner, J., Slade, B. A.
2011; 127: S65-S73

- **Decoupling age from cytomegalovirus-associated changes in the immune system**
Furman, D., Shen-Orr, S., Kidd, B., Maecker, H., Dekker, C., Davis, M.
AMER ASSOC IMMUNOLOGISTS.2011
- **Strong antibody responses to influenza vaccination are associated with cell survival/proliferation and pro-apoptotic immune traits**
Furman, D., Kidd, B., Shen-Orr, S., Maecker, H., Dekker, C., Davis, M.
AMER ASSOC IMMUNOLOGISTS.2011
- **Plasmablast-derived polyclonal antibody response after influenza vaccination** *JOURNAL OF IMMUNOLOGICAL METHODS*
He, X., Sasaki, S., Narvaez, C. F., Zhang, C., Liu, H., Woo, J. C., Kemble, G. W., Dekker, C. L., Davis, M. M., Greenberg, H. B.
2011; 365 (1-2): 67-75
- **Varicella Zoster Disease of the Central Nervous System: Epidemiological, Clinical, and Laboratory Features 10 Years after the Introduction of the Varicella Vaccine** *JOURNAL OF INFECTIOUS DISEASES*
Pahud, B. A., Glaser, C. A., Dekker, C. L., Arvin, A. M., Schmid, D. S.
2011; 203 (3): 316-323
- **Vaccine effectiveness against laboratory-confirmed influenza in infants A matched case control study** *HUMAN VACCINES*
Cochran, L. W., Black, S., Klein, N. P., Dekker, C. L., Lewis, E., Reingold, A. L.
2010; 6 (9): 729-735
- **A Systemic age dependent defect in immune-cell signaling response induced by inflammation**
Shen-Orr, S., Furman, D., Kidd, B., Maecker, H., Dekker, C., Butte, A., Davis, M.
AMER ASSOC IMMUNOLOGISTS.2010
- **Preterm Infants' T Cell Responses to Inactivated Poliovirus Vaccine** *JOURNAL OF INFECTIOUS DISEASES*
Klein, N. P., Gans, H. A., Sung, P., Yasukawa, L. L., Johnson, J., Sarafanov, A., Chumakov, K., Hansen, J., Black, S., Dekker, C. L.
2010; 201 (2): 214-222
- **Analyzing Immune Responses to the Seasonal Influenza Vaccine to Understand Immunosenescence**
Furman, D., Shen-Orr, S., Dekker, C., Maecker, H., Davis, M.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2010: S15
- **Differential maternal responses to a newly developed vaccine information pamphlet** *VACCINE*
Klein, N. P., Kissner, J., Aguirre, A., Sparks, R., Campbell, S., Edwards, K. M., Dekker, C. L., Shui, I., Gust, D. A.
2009; 28 (2): 323-328
- **Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults** *VACCINE*
Keitel, W. A., Dekker, C. L., Mink, C., Campbell, J. D., Edwards, K. M., Patel, S. M., Ho, D. Y., Talbot, H. K., Guo, K., Noah, D. L., Hill, H.
2009; 27 (47): 6642-6648
- **One Step Closer to a CMV Vaccine** *NEW ENGLAND JOURNAL OF MEDICINE*
Dekker, C. L., Arvin, A. M.
2009; 360 (12): 1250-1252
- **Adolescent Vaccination Recommendations from the National Vaccine Advisory Committee** *AMERICAN JOURNAL OF PREVENTIVE MEDICINE*
Freed, G. L.
2009; 36 (3): 278-279
- **Recurrent sterile abscesses following aluminium adjuvant-containing vaccines.** *BMJ case reports*
Klein, N. P., Edwards, K. M., Sparks, R. C., Dekker, C. L.
2009; 2009
- **An algorithm for treatment of patients with hypersensitivity reactions after vaccines** *PEDIATRICS*
Wood, R. A., Berger, M., Dreskin, S. C., Setse, R., Engler, R. J., Dekker, C. L., Halsey, N. A.
2008; 122 (3): E771-E777
- **Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses** *PLOS ONE*
Sasaki, S., He, X., Holmes, T. H., Dekker, C. L., Kemble, G. W., Arvin, A. M., Greenberg, H. B.

2008; 3 (8)

- **The promise and challenge of adolescent immunization** *AMERICAN JOURNAL OF PREVENTIVE MEDICINE*
Freed, G. L., Almquist, J. R., Birkhead, G. S., Dekker, C., Feinberg, M., Fergie, J., Gordon, L. K., Hinman, A. R., Humiston, S. G., Johnson, C., Mein, J. O., Koslap-Petraco, M. B., Lovell, et al
2008; 35 (2): 152-157
- **Mandates for adolescent immunizations - Recommendations from the National Vaccine Advisory Committee** *AMERICAN JOURNAL OF PREVENTIVE MEDICINE*
Freed, G. L., Almquist, J. R., Birkhead, G. S., Dekker, C., Feinberg, M., Fergie, J., Gordon, L. K., Hinman, A. R., Humiston, S. G., Johnson, C., Klein, J. O., Koslap-Petraco, M. B., Lovell, et al
2008; 35 (2): 145-151
- **Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine** *VACCINE*
Talbot, H. K., Keitel, W., Cate, T. R., Treanor, J., Campbell, J., Bradye, R. C., Graham, I., Dekker, C. L., Ho, D., Winokur, P., Walter, E., Bennet, J., Formica, et al
2008; 26 (32): 4057-4061
- **Baseline Levels of Influenza-Specific CD4 Memory T-Cells Affect T-Cell Responses to Influenza Vaccines** *PLOS ONE*
He, X., Holmes, T. H., Sasaki, S., Jaimes, M. C., Kemble, G. W., Dekker, C. L., Arvin, A. M., Greenberg, H. B.
2008; 3 (7)
- **Phenotypic changes in influenza-specific CD8(+) T cells after immunization of children and adults with influenza vaccines** *26th Annual Meeting of the American-Society-for-Virology*
He, X., Holmes, T. H., Mahmood, K., Kemble, G. W., Dekker, C. L., Arvin, A. M., Greenberg, H. B.
UNIV CHICAGO PRESS.2008: 803-11
- **Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults** *JOURNAL OF INFECTIOUS DISEASES*
Bernstein, D. I., Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K., Graham, I. L., Noah, D. L., He, F., Hill, H.
2008; 197 (5): 667-675
- **Risk factors for developing apnea after immunization in the neonatal intensive care unit** *PEDIATRICS*
Klein, N. P., Massolo, M. L., Greene, J., Dekker, C. L., Black, S., Escobar, G. J.
2008; 121 (3): 463-469
- **A role for genetics in the immune response to the varicella vaccine** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Klein, N. P., Fireman, B., Enright, A., Ray, P., Black, S., Dekker, C. L.
2007; 26 (4): 300-305
- **Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Zeman, A. M., Holmes, T. H., Stamatis, S., Tu, W., He, X., Bouvier, N., Kemble, G., Greenberg, H. B., Lewis, D. B., Arvin, A. M., Dekker, C. L.
2007; 26 (2): 107-115
- **Comparison of the influenza virus-specific effector and memory C-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines** *JOURNAL OF VIROLOGY*
Sasaki, S., Jaimes, M. C., Holmes, T. H., Dekker, C. L., Mahmood, K., Kemble, G. W., Arvin, A. M., Greenberg, H. B.
2007; 81 (1): 215-228
- **Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines** *JOURNAL OF VIROLOGY*
He, X., Holmes, T. H., Zhang, C., Mahmood, K., Kemble, G. W., Lewis, D. B., Dekker, C. L., Greenberg, H. B., Arvin, A. M.
2006; 80 (23): 11756-11766
- **Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults** *VACCINE*
Klein, N. P., Holmes, T. H., Sharp, M. A., Heineman, T. C., Schleiss, M. R., Bernstein, D. I., Kemble, G., Arvin, A. M., Dekker, C. L.
2006; 24 (33-34): 5913-5918
- **T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus** *JOURNAL OF CLINICAL INVESTIGATION*
He, X. S., Draghi, M., Mahmood, K., Holmes, T. H., Kemble, G. W., Dekker, C. L., Arvin, A. M., Parham, P., Greenberg, H. B.
2004; 114 (12): 1812-1819
- **Selective developmental defects of cord blood antigen-presenting cell subsets** *HUMAN IMMUNOLOGY*

- Drohan, L., Harding, J. J., Holm, B., Cordoba-Tongson, E., Dekker, C. L., Holmes, T., Maecker, H., Mellins, E. D.
2004; 65 (11): 1356-1369
- **Intestinal Imaging of children with acute rotavirus gastroenteritis** *JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION*
Bass, D., Cordoba, T., Dekker, T., Schuind, A., Cassady, J.
2004; 39 (3): 270-274
 - **Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood** *40th Annual Meeting of the Infectious-Diseases-Society-of-America*
Chen, S. F., Tu, W. W., Sharp, M. A., Tongson, E. C., He, X. S., Greenberg, H. B., Holmes, T. H., Wang, Z. T., Kemble, G., Manganello, A. M., Adler, S. P., Dekker, C. L., Levvis, et al
UNIV CHICAGO PRESS.2004: 1619-27
 - **Persistent and selective deficiency of CD4(+) T cell immunity to cytomegalovirus in immunocompetent young children** *JOURNAL OF IMMUNOLOGY*
Tu, W. W., Chen, S., Sharp, M., Dekker, C., Manganello, A. M., Tongson, E. C., Maecker, H. T., Holmes, T. H., Wang, Z. T., Kemble, G., Adler, S., Arvin, A., Lewis, et al
2004; 172 (5): 3260-3267
 - **Pediatric uses of valacyclovir, penciclovir and famciclovir** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Dekker, C. L., Prober, C. G.
2001; 20 (11): 1079-1081
 - **Antiviral agents effective against herpesviruses.** *Current clinical topics in infectious diseases*
Dekker, C. L., Prober, C. G.
2001; 21: 271-301
 - **Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials** *37th Interscience Conference on Antimicrobial Agents and Chemotherapy*
Corey, L., Langenberg, A. G., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, J. M., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., DiCarlo, R., Adimora, A. A., Leone, et al
AMER MEDICAL ASSOC.1999: 331-40
 - **Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial** *JOURNAL OF INFECTIOUS DISEASES*
Straus, S. E., Wald, A., KOST, R. G., McKenzie, R., Langenberg, A. G., Hohman, P., LEKSTROM, J., Cox, E., Nakamura, M., Sekulovich, R., Izu, A., Dekker, C., Corey, et al
1997; 176 (5): 1129-1134
 - **Safety and immunogenicity of Chiron/Biocrine(R) recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Black, S. B., Shinefield, H. R., Bergen, R., Hart, C., KREMERS, R., LAVETTER, A., LEMESURIER, J., Morozumi, P. A., Ray, P., Lewis, E. M., Fireman, B., Schwalbe, J., Hallam, et al
1997; 16 (1): 53-58
 - **Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59** *AIDS RESEARCH AND HUMAN RETROVIRUSES*
Keefer, M. C., Graham, B. S., McElrath, M. J., Matthews, T. J., Stablein, D. M., Corey, L., Wright, P. F., LAWRENCE, D., Fast, P. E., Weinhold, K., Hsieh, R. H., Chernoff, D., Dekker, et al
1996; 12 (8): 683-693
 - **A RECOMBINANT GLYCOPROTEIN VACCINE FOR HERPES-SIMPLEX TYPE-2 - SAFETY AND EFFICACY** *ANNALS OF INTERNAL MEDICINE*
Langenberg, A. G., BURKE, R. L., ADAIR, S. F., SEKULOVICH, O., TIGGES, M., Dekker, C. L., Corey, L.
1995; 122 (12): 889-898
 - **CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS** *JOURNAL OF INFECTIOUS DISEASES*
Kahn, J. O., Sinangil, F., Baenziger, J., Murcar, N., Wynne, D., Coleman, R. L., Steimer, K. S., Dekker, C. L., Chernoff, D.
1994; 170 (5): 1288-1291
 - **PLACEBO-CONTROLLED TRIAL OF VACCINATION WITH RECOMBINANT GLYCOPROTEIN-D OF HERPES-SIMPLEX VIRUS TYPE-2 FOR IMMUNOTHERAPY OF GENITAL HERPES** *LANCET*

- Straus, S. E., Corey, L., BURKE, R. L., SAVARESE, B., Barnum, G., Krause, P. R., KOST, R. G., Meier, J. L., Sekulovich, R., ADAIR, S. F., Dekker, C. L. 1994; 343 (8911): 1460-1463
- **PILOT EVALUATION OF INFLUENZA-VIRUS VACCINE (IVV) COMBINED WITH ADJUVANT VACCINE**
Keitel, W., Couch, R., Bond, N., Adair, S., Vannest, G., Dekker, C.
1993; 11 (9): 909-913
 - **UNRECOGNIZED PERTUSSIS INFECTION IN ADOLESCENTS** *AMERICAN JOURNAL OF DISEASES OF CHILDREN*
Cromer, B. A., Goydos, J., Hackell, J., Mezzatesta, J., Dekker, C., Mortimer, E. A.
1993; 147 (5): 575-577
 - **INDUCTION AND ENHANCEMENT OF IMMUNE-RESPONSES TO HERPES-SIMPLEX VIRUS TYPE-2 IN HUMANS BY USE OF A RECOMBINANT GLYCOPROTEIN-D VACCINE** *JOURNAL OF INFECTIOUS DISEASES*
Straus, S. E., SAVARESE, B., TIGGES, M., Freifeld, A. G., Krause, P. R., Margolis, D. M., Meier, J. L., Paar, D. P., ADAIR, S. F., DINA, D., Dekker, C., BURKE, R. L.
1993; 167 (5): 1045-1052
 - **COMPARISON OF ACELLULAR AND WHOLE-CELL PERTUSSIS-COMPONENT DIPHTHERIA-TETANUS-PERTUSSIS VACCINES IN INFANTS** *JOURNAL OF PEDIATRICS*
Blumberg, D. A., Mink, C. M., Cherry, J. D., Johnson, C., Garber, R., Plotkin, S. A., Watson, B., Ballanco, G. A., Daum, R. S., Sullivan, B., Townsend, T. R., Brayton, J., Gooch, et al
1991; 119 (2): 194-204
 - **PROTECTIVE EFFICACY OF THE TAKEDA ACELLULAR PERTUSSIS-VACCINE COMBINED WITH DIPHTHERIA AND TETANUS TOXOIDS FOLLOWING HOUSEHOLD EXPOSURE OF JAPANESE CHILDREN** *AMERICAN JOURNAL OF DISEASES OF CHILDREN*
Mortimer, E. A., Kimura, M., Cherry, J. D., KUNOSAKAI, H., Stout, M. G., Dekker, C. L., Hayashi, R., Miyamoto, Y., Scott, J. V., Aoyama, T., Isomura, S., Iwata, T., KAMIYA, et al
1990; 144 (8): 899-904
 - **Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.** *journal of pediatrics*
Blumberg, D. A., Mink, C. M., Cherry, J. D., Reisinger, K. S., Blatter, M. M., Congeni, B. L., Dekker, C. L., Stout, M. G., Mezzatesta, J. R., Scott, J. V.
1990; 117 (1): 46-51
 - **COMPARISON OF ACELLULAR AND WHOLE-CELL PERTUSSIS-COMPONENT DTP VACCINES - A MULTICENTER DOUBLE-BLIND-STUDY IN 4-YEAR-OLD TO 6-YEAR-OLD CHILDREN** *AMERICAN JOURNAL OF DISEASES OF CHILDREN*
MORGAN, C. A., Blumberg, D. A., Cherry, J. D., Reisinger, K. S., Blatter, M. M., Blumer, J. L., Dekker, C. L., Stout, M. G., Christenson, P. D.
1990; 144 (1): 41-45
 - **VIRUS-RESISTANCE IN CLINICAL-PRACTICE** *JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY*
Dekker, C., ELLIS, M. N., McLaren, C., Hunter, G., Rogers, J., Barry, D. W.
1983; 12: 137-152
 - **INVITRO SENSITIVITY TO ACYCLOVIR IN GENITAL HERPES-SIMPLEX VIRUSES FROM ACYCLOVIR-TREATED PATIENTS** *JOURNAL OF INFECTIOUS DISEASES*
McLaren, C., Corey, L., DEKKET, C., Barry, D. W.
1983; 148 (5): 868-875
 - **OCULAR LESIONS IN MICE FOLLOWING INTRACEREBRAL INJECTION OF HERPES-SIMPLEX VIRUS TYPE-1** *INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE*
Peiffer, R. L., DEKKER, C. D., Siegel, F. L.
1983; 24 (8): 1070-1078